» Articles » PMID: 30672740

Information Technology-Assisted Treatment Planning and Performance Assessment for Severe Thalassemia Care in Low- and Middle-Income Countries: Observational Study

Abstract

Background: Successful models of information and communication technology (ICT) applied to cost-effective delivery of quality care in low- and middle-income countries (LMIC) are an increasing necessity. Severe thalassemia is one of the most common life-threatening noncommunicable diseases of children globally.

Objective: The aim was to study the impact of ICT on quality of care for severe thalassemia patients in LMIC.

Methods: A total of 1110 patients with severe thalassemia from five centers in India were followed over a 1-year period. The impact of consistent use of a Web-based platform designed to assist comprehensive management of severe thalassemia (ThalCare) on key indicators of quality of care such as minimum (pretransfusion) hemoglobin, serum ferritin, liver size, and spleen size were assessed.

Results: Overall improvements in initial hemoglobin, ferritin, and liver and spleen size were significant (P<.001 for each). For four centers, the improvement in mean pretransfusion hemoglobin level was statistically significant (P<.001). Four of five centers achieved reduction in mean ferritin levels, with two displaying a significant drop in ferritin (P=.004 and P<.001). One of the five centers did not record liver and spleen size on palpation, but of the remaining four centers, two witnessed a large drop in liver and spleen size (P<.01), one witnessed moderate drop (P=.05 for liver; P=.03 for spleen size), while the fourth witnessed a moderate increase in liver size (P=.08) and insignificant change in spleen size (P=.12).

Conclusions: Implementation of computer-assisted treatment planning and performance assessment consistently and positively impacted indexes reflecting effective delivery of care to patients suffering from severe thalassemia in LMIC.

Citing Articles

The Potential of mHealth as a Game Changer for the Management of Sickle Cell Disease in India.

Kumar R, Das A JMIR Mhealth Uhealth. 2021; 9(4):e25496.

PMID: 33847598 PMC: 8080143. DOI: 10.2196/25496.


Life expectancy and risk factors for early death in patients with severe thalassemia syndromes in South India.

Dhanya R, Sedai A, Ankita K, Parmar L, Agarwal R, Hegde S Blood Adv. 2020; 4(7):1448-1457.

PMID: 32282881 PMC: 7160270. DOI: 10.1182/bloodadvances.2019000760.

References
1.
De Silva S, Fisher C, Premawardhena A, Lamabadusuriya S, Peto T, Perera G . Thalassaemia in Sri Lanka: implications for the future health burden of Asian populations. Sri Lanka Thalassaemia Study Group. Lancet. 2000; 355(9206):786-91. DOI: 10.1016/s0140-6736(99)08246-x. View

2.
Gwatkin D, Bhuiya A, Victora C . Making health systems more equitable. Lancet. 2004; 364(9441):1273-80. DOI: 10.1016/S0140-6736(04)17145-6. View

3.
Ho W, Lin K, Wang J, Hwang J, Chung C, Lin D . Financial burden of national health insurance for treating patients with transfusion-dependent thalassemia in Taiwan. Bone Marrow Transplant. 2006; 37(6):569-74. DOI: 10.1038/sj.bmt.1705287. View

4.
Mathews V, George B, Deotare U, Lakshmi K, Viswabandya A, Daniel D . A new stratification strategy that identifies a subset of class III patients with an adverse prognosis among children with beta thalassemia major undergoing a matched related allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2007; 13(8):889-94. DOI: 10.1016/j.bbmt.2007.05.004. View

5.
Thacker N . Prevention of thalassemia in India. Indian Pediatr. 2007; 44(9):647-8. View